Prollenium Medical Technologies Inc. on PROFIT 500 List 2014
AURORA, ON, June 17, 2014 /CNW/ - The PROFIT 500 list, published in this summer's issue of PROFIT and on PROFITguide.com has once again ranked Prollenium Medical Technologies Inc. amongst the fastest-growing companies in Canada. The year marks the 26th anniversary of the list that acknowledges Canadian companies in all sectors on five-year revenue growth. Prollenium has marked a 143% growth in revenue from 2008 to 2013 and is proud to be recognized for it's 6th consecutive year on the PROFIT list.
Prollenium Medical Technologies Inc., founded in 2002 in Aurora, Ontario is a manufacturer and distributor of novel biomaterials used for tissue reconstruction. The company has found success in the B2B market by exporting to distributors around the globe. In the past year, Prollenium has ventured into the B2C market, selling directly to consumers in Canada. "We felt ready in Canada to take on a new chapter of Prollenium, to meet our customers face-to-face and introduce our extensive product line," says Vice President Khasha Ighanian.
PROFIT 500 has described members of this year's list as the "real drivers of the economy." These are the companies that go where the business is and are willing to take the risks needed for success. "When we started Prollenium as a company, we rolled the dice. When we decided to manufacture our own products here in Canada we rolled again. Business is all about the risks, the willingness to gamble," says CEO Ario Khoshbin. "It is the optimism, tenacity and experience of the employees at Prollenium who have led the company to where it is today."
The growth continues across all sectors at Prollenium. Employee count has risen more than 5 times since manufacturing moved in house in 2011 and the product line at Prollenium is continuously expanding as the company invests heavily in the research and development of new and innovative products. Prollenium plans to launch a new product line this summer both internationally and domestically and is currently in the process for FDA approval.
For more information, please visit www.prollenium.com
Prollenium Medical Technologies Inc. is a Canadian-based company, founded in 2002, dedicated to the research, design, manufacture and distribution of implantable polymers in the pharmaceutical/dermatological industry. The company is committed to providing innovative products worldwide that are safe and viable. Flagship product lines include Revanesse®, Phiderma® and RheoVital™.
SOURCE Prollenium Medical Technologies Inc.For further information: Brittany Edwards, 905.508.1469, firstname.lastname@example.org